Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Brutsche

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2016
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based studyP Neumair, L Joos, R Warschkow, et al.
Lung|December 16, 2014
Physical activity and the frequency of acute exacerbations in patients with chronic obstructive pulmonary diseaseM Schönmann, N A Sievi, C F Clarenbach, et al.
Respiration; International Review of Thoracic Diseases|February 15, 2013
Diagnosis and management of chronic obstructive pulmonary disease: the Swiss guidelines. Official guidelines of the Swiss Respiratory SocietyE W Russi, W Karrer, M Brutsche, et al.
Lung Cancer (Amsterdam, Netherlands)|June 15, 2014
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)M Joerger, F Baty, M Früh, et al.
The European Respiratory Journal|June 10, 2010
Determinants of change in airway reactivity over 11 years in the SAPALDIA population studyI Curjuric, E Zemp, J Dratva, et al.
The European Respiratory Journal|April 24, 2010
Prevalence of airflow obstruction in smokers and never-smokers in SwitzerlandP-O Bridevaux, N M Probst-Hensch, C Schindler, et al.
Thorax|December 10, 2009
Longitudinal change of prebronchodilator spirometric obstruction and health outcomes: results from the SAPALDIA cohortN M Probst-Hensch, I Curjuric, B Pierre-Olivier, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2016
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based studyP Neumair, L Joos, R Warschkow, et al.
Lung|December 16, 2014
Physical activity and the frequency of acute exacerbations in patients with chronic obstructive pulmonary diseaseM Schönmann, N A Sievi, C F Clarenbach, et al.
Respiration; International Review of Thoracic Diseases|February 15, 2013
Diagnosis and management of chronic obstructive pulmonary disease: the Swiss guidelines. Official guidelines of the Swiss Respiratory SocietyE W Russi, W Karrer, M Brutsche, et al.
Lung Cancer (Amsterdam, Netherlands)|June 15, 2014
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)M Joerger, F Baty, M Früh, et al.
The European Respiratory Journal|June 10, 2010
Determinants of change in airway reactivity over 11 years in the SAPALDIA population studyI Curjuric, E Zemp, J Dratva, et al.
The European Respiratory Journal|April 24, 2010
Prevalence of airflow obstruction in smokers and never-smokers in SwitzerlandP-O Bridevaux, N M Probst-Hensch, C Schindler, et al.
Thorax|December 10, 2009
Longitudinal change of prebronchodilator spirometric obstruction and health outcomes: results from the SAPALDIA cohortN M Probst-Hensch, I Curjuric, B Pierre-Olivier, et al.
Pageof 3